Key result
Liraglutide enhances ischemic perfusion and angiogenesis in diabetic mice via Nrf2 pathway activation.
Why the study?
Improving endothelial progenitor cell function is a promising strategy for diabetic vascular complications, but the effects and mechanisms of liraglutide on endothelial progenitor cell dysfunction remain unclear.
Does liraglutide improve endothelial progenitor cell function and promote ischemic angiogenesis in diabetic models?
Does liraglutide improve endothelial progenitor cell function and promote ischemic angiogenesis in diabetic models?
Liraglutide promotes endothelial progenitor cell function and ischemic angiogenesis under diabetic conditions through Nrf2 activation.
Answers are grounded in this paper and cite their sources.
May support exploration of liraglutide in diabetic ischemia; hypothesis-generating in animals and leaves human translation open.
The impairment in endothelial progenitor cell (EPC) functions results in dysregulation of vascular homeostasis and dysfunction of the endothelium under diabetic conditions. Improving EPC function has been considered as a promising strategy for ameliorating diabetic vascular complications. Liraglutide has been widely used as a therapeutic agent for diabetes. However, the effects and mechanisms of liraglutide on EPC dysfunction remain unclear. The capability of liraglutide in promoting blood perfusion and angiogenesis under diabetic conditions was evaluated in the hind limb ischemia model of diabetic mice. The effect of liraglutide on the angiogenic function of EPC was evaluated by cell scratch recovery assay, tube formation assay, and nitric oxide production. RNA sequencing was performed to assess the underlying mechanisms. Liraglutide enhanced blood perfusion and angiogenesis in the ischemic hindlimb of db/db mice and streptozotocin-induced type 1 diabetic mice. Additionally, liraglutide improved tube formation, cell migration, and nitric oxide production of high glucose (HG)-treated EPC. Assessment of liraglutide target pathways revealed a network of genes involved in antioxidant activity. Further mechanism study showed that liraglutide decreased the production of reactive oxygen species and increased the activity of nuclear factor erythroid 2-related factor 2 (Nrf2). Nrf2 deficiency attenuated the beneficial effects of liraglutide on improving EPC function and promoting ischemic angiogenesis under diabetic conditions. Moreover, liraglutide activates Nrf2 through an AKT/GSK3β/Fyn pathway, and inhibiting this pathway abolished liraglutide-induced Nrf2 activation and EPC function improvement. Overall, these results suggest that Liraglutide represents therapeutic potential in promoting EPC function and ameliorating ischemic angiogenesis under diabetic conditions, and these beneficial effects relied on Nrf2 activation.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2022) studied Diabetic hindlimb ischemia and endothelial progenitor cell dysfunction. Liraglutide vs. Vehicle (normal saline or PBS) was evaluated on Hindlimb blood perfusion recovery and capillary density (CD31 staining) in ischemic gastrocnemius muscle (p=<0.05). Liraglutide significantly enhanced ischemic hindlimb blood perfusion and angiogenesis in diabetic mice and restored high glucose-impaired EPC function via AKT/GSK-3β/Fyn-mediated Nrf2 activation.
Synapse has enriched 10 related papers. Consider them for comparative context: